Flare Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
64
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$85M
- Investors
-
15
Flare Therapeutics General Information
Description
Developer of a health-tech platform designed to offer small-molecule precision medicine for cancer patients. The company's platform specializes in transcription factors to discover precision medicines and treatments for neurology, rare genetic disorders, immunology, and inflammation, enabling medical professionals to change the trajectory of how to treat diseases.
Contact Information
Website
www.flaretx.comCorporate Office
- 400 Technology Square
- Suite 501
- Cambridge, MA 02139
- United States
Corporate Office
- 400 Technology Square
- Suite 501
- Cambridge, MA 02139
- United States
Flare Therapeutics Timeline
Flare Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 30-Jun-2026 | $85M | Completed | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC (Series B) | 22-Mar-2023 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC (Series A) | 13-May-2021 | $82M | $82M | Completed | Clinical Trials - Phase 1 |
Flare Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 82,000,000 | $0.001000 | $1 | $1 | 1x | $1 | 14.99% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Flare Therapeutics Comparisons
Industry
Financing
Details
Flare Therapeutics Competitors (6)
One of Flare Therapeutics’s 6 competitors is Cullgen, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cullgen | Formerly VC-backed | San Diego, CA | ||||
| Exo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Edgewise Therapeutics | Formerly VC-backed | Boulder, CO | ||||
| SEngine Precision Medicine | Formerly VC-backed | Bothell, WA | ||||
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA |
Flare Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Flare Therapeutics Patents
Flare Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025151478-A1 | Compounds and composition for targeting tp53-y220c mutants | Inactive | 09-Jan-2024 | ||
| WO-2025151549-A1 | Pyrido[3,2-b]indole-3-carbonitrile compounds and composition for targeting tp53-y220c mutants | Inactive | 09-Jan-2024 | ||
| EP-4808928-A1 | Degrader molecules targeting androgen receptor | Pending | 17-Nov-2023 | ||
| WO-2025106910-A1 | Degrader molecules targeting androgen receptor | Inactive | 17-Nov-2023 | ||
| AU-2024367019-A1 | Pparg inverse agonists and immunotherapies for treating cancer | Pending | 27-Oct-2023 | A61K45/06 |
Flare Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Flare Therapeutics Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eli Lilly and Company Foundation | Limited Partner | Minority | ||
| Agent Capital | Venture Capital | Minority | ||
| GordonMD Global Investments | PE/Buyout | Minority | ||
| Lilly USA | Corporation | Minority | ||
| Memorial Sloan Kettering Cancer Center | Accelerator/Incubator | Minority |
Flare Therapeutics FAQs
-
When was Flare Therapeutics founded?
Flare Therapeutics was founded in 2021.
-
Where is Flare Therapeutics headquartered?
Flare Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Flare Therapeutics?
Flare Therapeutics has 64 total employees.
-
What industry is Flare Therapeutics in?
Flare Therapeutics’s primary industry is Drug Discovery.
-
Is Flare Therapeutics a private or public company?
Flare Therapeutics is a Private company.
-
What is the current valuation of Flare Therapeutics?
The current valuation of Flare Therapeutics is .
-
What is Flare Therapeutics’s current revenue?
The current revenue for Flare Therapeutics is .
-
How much funding has Flare Therapeutics raised over time?
Flare Therapeutics has raised $290M.
-
Who are Flare Therapeutics’s investors?
Eli Lilly and Company Foundation, Agent Capital, GordonMD Global Investments, Lilly USA, and Memorial Sloan Kettering Cancer Center are 5 of 15 investors who have invested in Flare Therapeutics.
-
Who are Flare Therapeutics’s competitors?
Cullgen, Exo Therapeutics, Edgewise Therapeutics, SEngine Precision Medicine, and Blueprint Medicines are some of the 6 competitors of Flare Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
